GlassScriptPhysician profile
Christopher L Ozimek
NPI 1083607972
$2,663.92
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $217 · 2021: $309 · 2022: $329 · 2023: $601 · 2024: $408 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $521.81 | 2021-2025 | Azstarys |
| Tris Pharma INC | $315.69 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $272.26 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $154.28 | 2021-2023 | Qelbree |
| Neos Therapeutics, LP | $151.50 | 2019-2022 | |
| Adlon Therapeutics L.P. | $150.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $145.24 | 2024-2025 | |
| Sanofi Pasteur INC. | $138.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $133.52 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $96.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $87.37 | 2019-2024 | Bexsero, Pediarix |
| Seqirus USA INC | $81.05 | 2021-2025 | Flucelvax |
| Cranial Technologies, INC | $68.15 | 2019-2024 | Doc Band |
| Rhodes Pharmaceuticals L.P. | $62.42 | 2019 | |
| Collegium Pharmaceutical, INC. | $55.52 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $43.23 | 2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $42.84 | 2023-2024 | Flumist Quadrivalent |
| Sobi, INC | $35.10 | 2019-2023 | |
| Biogen, INC. | $29.45 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.26 | 2025 | Alvesco |
| Biomarin Pharmaceutical INC. | $17.89 | 2025 | Voxzogo 1.2mg |
| Avion Pharmaceuticals | $15.39 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $13.97 | 2024 | Relexxii |
| Arbor Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ozimek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.